Blood-Based Measurable Residual Disease by Clonotypic Mass Spectrometry is Prognostic in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant

发表于 2026-8-17 14:20:38

期刊：Clinical Lymphoma Myeloma and Leukemia

文献作者：Michael J. Slade; Julie Fortier; Abir Khaled; Mark Fiala; Zac McDonald; Mark A. Zaydman; Fei Wan; Mark A. Schroeder; Keith Stockerl-Goldstein; Liqiang Yang; Ravi Vij

出版日期：2025-9-

DOI号：10.1016/j.clml.2025.04.017

下载链接：https://www.sciencedirect.com/sc ... 15226502500148X/pdf

文献链接：https://doi.org/10.1016/j.clml.2025.04.017

当前文献来源于 Elsevier BV。

备注信息：

发表于 2026-8-17 14:20:39

: 当前求助已完成，请重新发起求助。
已完结状态的附件将会在24小时内删除。

[Elsevier/Sciencedirect] Blood-Based Measurable Residual Disease by Clonotypic Mass Spectrometry is Prognostic in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant

已采纳

同分类求助

最新回复

站点公告

今日热心研友

（热心研友QQ群）

[Elsevier/Sciencedirect] Blood-Based Measurable Residual Disease by Clonotypic Mass Spectrometry is Prognostic in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant 一键复制